



Organisation for Oncology and Translational Research
癌轉譯研究組織

2025 OOTR Scientific Board Meeting

CONFERENCE INFORMATION

Conference Name:
OOTR Scientific Board Meeting

Date:
20th December 2025

Time:
09:00 – 15:00 (HKT)

Venue:
Grand Ballroom 1, Hong Kong Ocean Park Marriott Hotel, Hong Kong

Organisers:
• Organisation for Oncology and Translational Research (OOTR)

Conference Chairpersons:
Organisation for Oncology and Translational Research (OOTR):

- Louis Wing Cheong Chow
- Masakazu Toi

Format:
• Offline
• Online Streaming

Content:

09:00 – 09:10	Opening Ceremony										
Session I: Novel Biomarkers & Strategies to Block Cancer Metastasis											
Chairpersons: Juanjuan Li (China), Chang Gong (China)											
09:10 – 10:10 (20 mins each)	<p>Speakers:</p> <ul style="list-style-type: none"> • Alfred S.K. Cheng (Hong Kong, China) • Wai Leong Tam (Singapore) • Soo Chin Lee (Singapore) 										
10:10 – 10:30	Morning Tea Break										
10:30 – 11:10 (20 mins each)	<p>Speakers:</p> <ul style="list-style-type: none"> • Zuoren Yu (China) • Wonshik Han (Korea) 										
11:10 – 11:30	<p><u>Discussion Session</u></p> <p>Discussants:</p> <table> <tr> <td>• Alfred S.K. Cheng (Hong Kong, China)</td> <td>• Chang Gong (China)</td> </tr> <tr> <td>• Wonshik Han (Korea)</td> <td>• Juanjuan Li (China)</td> </tr> <tr> <td>• Wai Leong Tam (Singapore)</td> <td>• Liming Chen (China)</td> </tr> <tr> <td>• Soo Chin Lee (Singapore)</td> <td>• Hyeon-Jeong Lee (China)</td> </tr> <tr> <td>• Zuoren Yu (China)</td> <td>• Chengcheng Gong (China)</td> </tr> </table>	• Alfred S.K. Cheng (Hong Kong, China)	• Chang Gong (China)	• Wonshik Han (Korea)	• Juanjuan Li (China)	• Wai Leong Tam (Singapore)	• Liming Chen (China)	• Soo Chin Lee (Singapore)	• Hyeon-Jeong Lee (China)	• Zuoren Yu (China)	• Chengcheng Gong (China)
• Alfred S.K. Cheng (Hong Kong, China)	• Chang Gong (China)										
• Wonshik Han (Korea)	• Juanjuan Li (China)										
• Wai Leong Tam (Singapore)	• Liming Chen (China)										
• Soo Chin Lee (Singapore)	• Hyeon-Jeong Lee (China)										
• Zuoren Yu (China)	• Chengcheng Gong (China)										
Session II: Design of Biomarker-led Clinical Trials											
Chairpersons: Masakasu Toi (Japan), Shuqun Zhang (China), Yabing Cao (Macau, China)											
11:30 – 12:10 (20 mins each)	<p>Speakers:</p> <ul style="list-style-type: none"> • Satoshi Morita (Japan) • Fengfeng Cai (China) 										

12:10 – 12:30	<p><u>Discussion Session</u></p> <p>Discussants:</p> <ul style="list-style-type: none"> • Fengfeng Cai (China) • Masakasu Toi (Japan) • Shuqun Zhang (China) • Yabing Cao (Macau, China) • Huimin Zhang (China) • Siwen Sun (China) • Wei Wang (China)
<p>Session III: Organoids Research and its Application</p> <p>Chairpersons: Haidong Zhao (China), Mingang Ying (China), Zhigang Yu (China)</p>	
12:30 – 13:30 (20 mins each)	<p>Speakers:</p> <ul style="list-style-type: none"> • Rebecca Y.M. Chin (Hong Kong, China) • King Lun Yueng (Hong Kong, China) • Gary M.K. Tse (Hong Kong, China)
13:30 – 13:50	Afternoon Tea Break
13:50 – 14:30 (20 mins each)	<p>Speakers:</p> <ul style="list-style-type: none"> • Louis W.C. Chow (Hong Kong, China) • Naoya Sakamoto (Japan)
14:30 – 14:50	<p><u>Discussion Session</u></p> <p>Discussants:</p> <ul style="list-style-type: none"> • Rebecca Y.M. Chin (Hong Kong, China) • King Lun Yueng (Hong Kong, China) • Gary M.K. Tse (Hong Kong, China) • Naoya Sakamoto (Japan) • Louis W.C. Chow (Hong Kong, China) • Mingang Ying (China) • Zhigang Yu (China) • Haidong Zhao (China) • Weiling Chen (China) • Jiefeng Huang (China)
14:50 – 15:00	Conclusion & Closing Ceremony



Organisation for Oncology and Translational Research

癌轉譯研究組織

About OOTR

Organisation for Oncology and Translational Research

OOTR is a non-profit international organisation that conducts Translational Research in Asia Pacific, formed by Dr. Louis Wing Cheong Chow, a Hong Kong-based breast cancer specialist and Dr. Masakazu Toi, a Japan-based surgeon-oncologist in the year of 2002.

OOTR aims to guide the latest scientific findings towards helping improve cancer treatment and prevention. We believe it is essential to develop new modalities and to implement translational research on cancer which allows the results from basic studies to apply to clinical settings such as cancer prevention, diagnosis and treatment. We place a strong emphasis on developing clinical oncology and moving towards translational research.

With the above aim in mind, we seek to create networking among oncologists and to develop effective interaction among the most advanced academic institutions throughout the world. We hope that through these vital exchanges, new thinking and discoveries will give rise to faster and better ways to fight cancer.